BIAL Goes Global With New US Research Center and Acquisition of Promising Parkinson's Disease Programs
BIAL, a pharmaceutical company based in Portugal with locations across Europe and dedicated to R&D in CNS diseases, announced today that it has established a new affiliate in the United States of America, BIAL Biotech Investments Inc. (BIAL Biotech). This new research center focused on genetically-defined Parkinson’s disease is based in Cambridge, Massachusetts, a prominent biotech hub in the world.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201001005323/en/
Simultaneously, BIAL announced that it has acquired worldwide rights of LTI-291 and all the Parkinson’s disease research programs of Lysosomal Therapeutics Inc. (LTI) and taken on the entire R&D team.
António Portela, executive president of BIAL, reveals: “Our entry into the US with the creation of BIAL Biotech and the acquisition of the promising programs from LTI, is a decisive step towards the fulfilment of our mission to contribute to improving the quality of life of people worldwide. The development of this new research center in the US, is a landmark of enormous relevance for us. We are investing in science and research, through our direct presence in one of the most important research hubs in the world and in one of the most promising areas of medicine.”
This acquisition not only provides the company with a pipeline of new product candidates in Parkinson’s disease but also an experienced R&D team, led by Peter Lansbury, professor of neurology at Harvard Medical School and a recognized thought leader in the field of neurodegenerative diseases.
With this acquisition, BIAL is expanding its pipeline, namely with the integration of new compounds in neurodegeneration already in clinical development, specifically for Parkinson's disease, where the pharmaceutical company already has a significant market position.
The executive president of BIAL also points out: “The compounds we’ve acquired are based on genetics, a new field of research for us. The lead asset, which now has the code name 'BIA 28-6156/LTI-291', has an innovative mechanism of action and presents the potential of being a first disease-modifying therapy for a genetic subset of Parkinson’s disease. It has successfully completed a Phase I trial program and should be ready to start Phase II studies in 2021. We´re progressing from symptomatic treatment to an intervention in the mechanisms of the disease, which is very exciting for BIAL.”
“We are happy to be part of BIAL and take the lead on the growth story in the US,” says Kees Been, former CEO of LTI and now CEO of BIAL Biotech. "With the commitment and resources of BIAL we will be able to accelerate our novel clinical and research programs as targeted and personalized treatment approaches for genetically-defined PD patients.”
“On behalf of the LTI shareholders, I want to express our enthusiastic endorsement of BIAL as a good home for the programs of LTI,” said Clay B. Thorp, General Partner, Hatteras Venture Partners. “This deal is a perfect fit and we have great confidence that the team, with the resources and commitment of BIAL, will advance LTI-291 and the other compounds rapidly to patients to treat this debilitating form of Parkinson’s disease.”
BIA 28-6156 / LTI-291 is a drug compound aimed at treating patients with GBA-Associated Parkinson’s diseases (GBA-PD) caused by an underlying mutation in the GBA1 gene. This genetic mutation affects approximately 10% to 15% of Parkinson’s disease patients (100,000-150,000 patients in the US) and is a validated risk factor that generally leads to an earlier age of disease onset and more rapid disease progression.
In addition to an upfront payment, the total value of the deal could reach up to 130 million dollars, based on attainment of a series of milestone payments as the assets progress through the clinic and into the market. Other financial terms will not be disclosed.
About BIAL Biotech
BIAL Biotech is a Center of Excellence for the development of genetically-defined Parkinson’s disease therapeutics located in the heart of the Boston biotech cluster. BIAL Biotech is a wholly owned subsidiary of BIAL, a pharmaceutical company based in Portugal with locations across Europe.
Founded in 1924, BIAL's mission is to research, develop and provide therapeutic solutions within the area of health. In the last decades, BIAL has focused strategically on quality, innovation and internationalisation. BIAL is strongly committed to therapeutic innovation, investing more than 20% of its annual turnover into research and development within neurosciences and the cardiovascular system. The company expects to introduce new drugs on the market in the coming years, strengthening its international presence based on proprietary drugs and achieving its goal of supplying innovative products to patients worldwide.
For more information on BIAL: www.bial.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Western Union Expands Real-Time Payout26.10.2020 13:00:00 CET | Press release
Western Union (NYSE: WU), a global leader in cross-border, cross-currency money movement and payments, announced it has further expanded its global digital network for funds payout and increased the availability of real-time payouts, advancing the company’s goal of building the world’s largest funds collection and distribution network to meet the growing customer demand for transparency, immediacy, and reliability. For decades, Western Union has been moving money with payout in minutes in over 130 currencies through its vast global retail network of over 550,000 agent locations across more than 200 countries and territories. The company now also expanded its account-based payout options, including bank account, wallet, or card payout in over 120 countries (up from 100) with real-time payment speeds in 80 of these countries (up from 50 in April 2020).1 The capability is available for its customers and clients across its branded, co-branded partner, and white-label partner money transfer
Hologic Launches 3DQuorum™ Imaging Technology, Powered by Genius AI™, in Europe26.10.2020 13:00:00 CET | Press release
Hologic, Inc. (Nasdaq: HOLX) today announced the commercial availability in Europe of its 3DQuorum™ Imaging Technology, Powered by Genius AI™. The innovation was designed to help improve mammography efficiency and workflow, which is critical as clinics strive to manage the backlog of women whose routine breast screening was delayed due to the COVID-19 lockdown. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201026005023/en/ 3DQuorum™ Imaging Technology, Powered by Genius AI™ (Graphic: Business Wire) The 3DQuorum technology uses Genius AI-powered analytics to reconstruct high-resolution 3D data to produce 6mm “SmartSlices.” These analytics identify clinically relevant regions of interest and preserve important features during reconstruction of the SmartSlices.1,2 SmartSlices expedite read time by reducing the number of images for radiologists to review, without compromising image quality, sensitivity or accuracy.1,2 With 3DQu
PerkinElmer Receives CE Mark for Multi-analyte Respiratory Panel Including COVID-1926.10.2020 13:00:00 CET | Press release
PerkinElmer, Inc. (NYSE: PKI) announced today that its PKamp™ Respiratory SARS-CoV-2 RT-PCR Panel has received clearance to be marketed as an in vitro diagnostic (IVD) device in more than 30 countries by meeting the requirements of the European In Vitro Diagnostic Directive (IVDD). This test is currently under review by the U.S. FDA for Emergency Use Authorization (EUA). The multi-analyte panel enables labs to detect and differentiate between SARS-CoV-2, influenza A viruses, influenza B viruses and respiratory syncytial virus (RSV) in a single test, which will be critical to manage the surge in test demand during the flu season as the targeted pathogens have some similar signs and symptoms. Rather than running multiple tests on samples, the PKamp Respiratory SARS-CoV-2 RT-PCR Panel is designed to conserve resources by testing a single nasopharyngeal, oropharyngeal or nasal swab sample collected from individuals suspected of respiratory viral infection consistent with COVID-19, the flu
FDA Grants 510(k) Clearance for Abiomed’s Innovative Cardiopulmonary Support Technology26.10.2020 12:55:00 CET | Press release
The United States Food and Drug Administration (FDA) has granted Abiomed (NASDAQ: ABMD) a 510(k) clearance for an all-in-one, compact cardiopulmonary bypass system called the Abiomed Breethe OXY-1 System™. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201026005299/en/ The Abiomed Breethe OXY-1 System has received 510(k) clearance from the United States FDA (Photo: Buisness Wire) The ECMO system provides cardiopulmonary bypass support for patients whose lungs can no longer provide sufficient end organ oxygenation. The 510(k) clearance is to pump, oxygenate, and remove carbon dioxide from blood during cardiopulmonary bypass for up to six hours. The system can help provide oxygenation to patients suffering from cardiogenic shock or respiratory failure such as ARDS, H1N1, SARS, or COVID-19. When used with the Impella heart pump it can unload the heart and oxygenate the body, a combination therapy known as ECpella. Abiomed’s Bre
NTTVC Publicly Announces $500 Million Fund Created in Partnership with NTT26.10.2020 12:40:00 CET | Press release
NTTVC today publicly announced its $500 million fund to help startups reach rapid global scale by harnessing the power of partnership. The independent venture capital firm was founded by entrepreneur and investor Vab Goel in collaboration with global technology service provider NTT. The firm is also announcing investments in five startups delivering impactful innovations for businesses and consumers: Celona, Eko, nference, Shoreline and UDP Labs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201026005262/en/ NTTVC Founding Partner Vab Goel and Partner Fay Hazaveh Costa (Photo: Business Wire) NTTVC invests broadly across all stages and sectors, with an emphasis on the future of enterprise, digital health and innovations powered by AI, machine learning and data. By combining the deep relationships of its investment team with the reach of NTT, the firm offers access to a robust network of industry experts, customers, entrepren
SoftServe Achieves Premier Consulting Partner Status in AWS Partner Network26.10.2020 12:00:00 CET | Press release
SoftServe, a leading digital authority and consulting company, announces it has achieved Premier Consulting Partner status in the Amazon Web Services (AWS) Partner Network (APN). The APN Premier Consulting Partner status differentiates SoftServe as an APN Partner that demonstrates expertise and notable success in helping customers design, architect, build, migrate, and manage workloads on AWS. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201026005082/en/ (Graphic: Business Wire) “We are committed to our clients’ success in realizing the advantages of AWS to transform and future-proof their business, delivering end-to-end solutions that solve complex enterprise challenges while enhancing speed, agility, and scalability,” said Andrew Greene - Associate Vice President, Global Partnerships & Alliances at SoftServe. “We are excited to join the ranks of APN Premier Consulting Partners who have proven expertise at the highest lev
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom